Thymalfasin (Thymosin Alpha-1) for Chronic Hepatitis B: A Comprehensive Drug Review
Thymalfasin (thymosin alpha-1) showed sustained virological response rates of 25-40% as monotherapy for chronic hepatitis B, with superior durability compared to interferon and a much better safety profile.
Quick Facts
What This Study Found
Thymalfasin achieved 25-40% sustained virological response in chronic HBV with response rates increasing over follow-up (unlike interferon relapse), superior safety profile, and durable immune-mediated viral control.
Key Numbers
How They Did This
Comprehensive drug review covering thymalfasin mechanism (T-cell, NK, DC activation), clinical trial data (monotherapy and combinations), sustained response rates, and safety profile.
Why This Research Matters
Chronic HBV affects 300 million people. A well-tolerated drug with durable responses that improve over time addresses the biggest limitation of existing therapies — treatment durability.
The Bigger Picture
Thymalfasin's increasing response over time suggests it induces true immune reconversion — the immune system learning to permanently control HBV — rather than just temporary suppression.
What This Study Doesn't Tell Us
Review of available trial data through 2004. Some trials had small sample sizes. The mechanism of increasing response over time was not fully explained.
Questions This Raises
- ?Could thymalfasin achieve functional HBV cure?
- ?Should it be first-line therapy for chronic HBV?
- ?Does combining with nucleos(t)ide analogs improve response further?
Trust & Context
- Key Stat:
- Responses improve over time Unlike interferon where responders can relapse, thymalfasin responses INCREASE over extended follow-up — suggesting durable immune reconversion
- Evidence Grade:
- Moderate evidence from a comprehensive review of multiple clinical trials with consistent response and safety data.
- Study Age:
- Published in 2004. Thymalfasin is approved in 30+ countries for HBV and continues to be studied in combination with antivirals.
- Original Title:
- Thymalfasin for the treatment of chronic hepatitis B.
- Published In:
- Expert review of anti-infective therapy, 2(1), 9-16 (2004)
- Authors:
- Chien, Rong-Nan, Liaw, Yun-Fan(2)
- Database ID:
- RPEP-00896
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is thymosin alpha-1 effective for hepatitis B?
Yes — it achieves 25-40% sustained viral response as monotherapy, with the unique advantage that response rates improve over time as the immune system learns to control the virus.
Is it better than interferon?
Similar cure rates but much better tolerated — far fewer side effects. And unlike interferon where some responders relapse, thymalfasin responses tend to increase over time.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00896APA
Chien, Rong-Nan; Liaw, Yun-Fan. (2004). Thymalfasin for the treatment of chronic hepatitis B.. Expert review of anti-infective therapy, 2(1), 9-16.
MLA
Chien, Rong-Nan, et al. "Thymalfasin for the treatment of chronic hepatitis B.." Expert review of anti-infective therapy, 2004.
RethinkPeptides
RethinkPeptides Research Database. "Thymalfasin for the treatment of chronic hepatitis B." RPEP-00896. Retrieved from https://rethinkpeptides.com/research/chien-2004-thymalfasin-for-the-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.